Mirati Therapeutics, Inc. (NASDAQ:MRTX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) have been assigned a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the firm, MarketBeat Ratings reports. Eleven research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average […]

Leave a Reply

Your email address will not be published.

Previous post Freshpet, Inc. (NASDAQ:FRPT) Receives $89.14 Consensus Target Price from Analysts
Next post 3M (NYSE:MMM) Receives $105.20 Average Price Target from Analysts